Browse by author
Lookup NU author(s): Dr Stephen Thompson, Emeritus Professor Colin Self
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The very cytotoxic potency of therapeutic antibodies used in the fight against cancer makes their specific tumour targeting of crucial importance. Unfortunately, in practice, this is often not achieved and can lead to dangerous side-effects. A way of greatly reducing such side-effects is to make the antibodies region-specific to the areas bearing tumour. This can now be achieved by rendering them light dependent so they are only active where illuminated. There are many ways of employing such light-enhanced targeting in very many locations within the body. When it is applied to direct killer T-cells to ovarian primary tumours, not only is primary tumour growth markedly reduced but also a dramatic reduction of metastatic growth is observed in the liver.
Author(s): Thompson S, Self AC, Self CH
Publication type: Review
Publication status: Published
Journal: Drug Discovery Today
Year: 2010
Volume: 15
Issue: 11-12
Pages: 468-473
Print publication date: 05/05/2010
ISSN (print): 1359-6446
ISSN (electronic): 1878-5832
Publisher: ELSEVIER SCI LTD
URL: http://dx.doi.org/10.1016/j.drudis.2010.04.006
DOI: 10.1016/j.drudis.2010.04.006
